Jessaziekenhuis Hasselt
Hasselt, Limburg, 3500, Belgium
NCT Number: NCT02575053
Study objectives
Primary objective:
This study wants to evaluate the safety of a latex safe protocol as proposed by the Australasian Society of Clinical Immunology and Allergy. In other words,the investigators hope to demonstrate that patients with known latex allergy or latex sensitisation can be treated safely in operating theatres without special requirements towards scheduling provided that all powdered latex gloves are removed from the OR environment( preparation rooms, theatres, recovery room and surroundings). In contrast, earlier guidelines require the theatre to be left unused during at least 3 hours before a patient with suspected latex allergy can be operated on in this theatre.
Secondary objectives:
* The investigators want to evaluate to what extend patients who report a latex allergy show risk factors of latex allergy. * To investigate to what extend latex allergy was proven by laboratory testing or skin testing in patients who report a latex allergy. * Type of latex allergic reaction when patients report a latex allergy. * The level of satisfaction of surgeons and OR scheduling staff with the new latex safe protocol and with the switching to powder free latex gloves.
Looking for future studies?
Notify MeAll sexes
Observational
Hasselt, Limburg, 3500, Belgium
Introduction
Allergic reactions to natural rubber latex( NRL, or Latex) are an important issue in daily anesthesia practice. Latex allergy may result in lesions consistent with irritation dermatitis and type 4 allergic contact dermatitis. But it may also result in type 1 allergic reactions which are potentially lethal.(1) The prevalence of latex allergy in a general population is estimated less than 1%, but sensitization can rise up to 5.4-7.6%.(3,4) In certain populations at risk, the prevalence of latex allergy and sensitization rises up to 17% in health care workers an even 73% in patients who were exposed to latex on a regular basis( eg. Patients with spina bifida).
These patients require special logistic and organizational requirements during their stay in the operating room. Nowadays, both guidelines from the Belgian Society of Anesthesiology and Resuscitation(BVAR-SARB) as the American Association of Anesthesiologists recommend these patients to be scheduled as the first case of the day.(1,3) In this way, these patients are treated in an environment with a minimal amount of airborne latex particles. After all, studies have proven that using powdered latex gloves causes a substantial contamination of the operating room. Latex particles can even remain airborne up to 5 hours afterwards.(1,3,5).
In consequence, the guidelines mentioned earlier dictate patients with a (high risk for) latex allergy to be treated in an operating theatre left unused during at least 3 to 6 hours.(1,2,6) Of course, such requirements can result in organizational problems potentially resulting in delaying procedures, financial losses, patient discomfort and dissatisfaction with both patients as well as hospital staff.
The last years, some professionals have suggested the idea that planning these patients as first case of the day is no longer necessary because of certain technical evolutions in current operating room practice.(7) In a guideline published by the Australasian Society of Clinical Immunology and Allergy (last updated March 2010), patients at risk or with known latex allergy are no longer scheduled as first case of the day. However, this requires the removal of all powdered latex gloves from the OR (including pre-anesthesia unit, operating theatres, post anesthesia care unit and surroundings).(8) The requirement for a completely latex free environment en materials when operating on a actual patient with (suspected) latex allergy remains unchanged.
Although several studies have shown the importance of powdered gloves in the spread of airborne latex particles and the basis for this protocol seams acceptable and logical, there is currently no literature confirming the safety of this practice in a clinical setting.
Study objective
Primary objective:
This study wants to evaluate the safety of a latex safe protocol as proposed by the Australasian Society of Clinical Immunology and Allergy. In other words,the investigators hope to demonstrate that patients with known latex allergy or latex sensitisation can be treated safely in operating theatres without special requirements towards scheduling provided that all powdered latex gloves are removed from the OR environment (preparation rooms, theatres, recovery room and surroundings). In contrast, earlier guidelines require the theatre to be left unused during at least 3 hours before a patient with suspected latex allergy can be operated on in this theatre.
Secondary objectives:
Study procedure
Pre-operative setting:
Medical history, including allergies of every patient will be assessed . Every patient with (suspected) latex allergy who will undergo surgery will be approached to participate in this study. There are no restrictions regarding type of surgery.
The research team will ask all eligible patients to sign an informed consent. The researchers will ask all patients who are willing to participate to complete a short questionnaire.
Patients refusing to participate will be treated by the same protocol. However, they will not be contacted in order to provide further medical data in relation to this study.
During the stay in the OR:
Nursing staff and the anesthesiologist perform a time-out procedure prior to surgery. A (suspected) latex allergy is marked in the electronic case file. The software registers this cases and sends a confirmation to the research team.
At the end of the procedure, the anesthesiologist marks if a latex allergic reaction has occurred through a pop -up in the electronic case file.
Post-operative setting:
The patient receives a short note, explaining that the research team will contact him/her after 72 hours.
Types of latex reactions:
Based on B-cell mediated production of IgE (immunoglobulin E) antibodies towards Hev b latex proteins after a first exposure. Symptoms already occur after a few minutes up to 1 hour, depending of the route of exposure (inhalation, parenteral or mucous membrane exposure). The severity of the reaction also varies in relation to the route of exposure. Type 1 allergic reactions in response to latex exposure may be lethal.(1,2,3)
Note:
Satisfaction about the newly implemented protocol:
Starting from 01-02-2016, the research team will investigate the level of satisfaction about the newly implemented protocol by means of a short questionnaire( written or E-mail) sent to all involved surgeons and OR scheduling staff.
With this questionnaire, the investigators want to evaluate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.
All latex containing materials should be removed from the room and latex free alternatives should be available.
Time frame: 72 hours after surgery
The research team wants to investigate how many latex allergic reactions occur. types:
itching, erythema, a burning sensation, blistering, flakiness and fissuring of the skin. Never life-threatening.
B-cell mediated production of IgE antibodies towards Hev b latex proteins. Symptoms: after a few minutes up to 1 hour, depending of the route of exposure( inhalation, parenteral,mucous membrane exposure). Severity also varies in relation to the route of exposure. Potentially lethal anaphylaxis.
Time frame: baseline
Time frame: baseline
To what extend do patients who report a latex allergy show risk factors such as:
Congenital defects of the genito-urinary tract
Spina bifida
Meningomyelocoele
a medical history consisting of multiple surgical procedures
Food allergies (tropical fruit, nuts, stone fruit, avocado, others)
Atopic constitution( asthma, eczema, rhinitis, hay fever)
Professional exposure( hairdressers, health care workers, latex exposure in latex industries or chemical related jobs)
(anaphylaxis of unknown origin during previous hospital stays or procedures)
Time frame: Assessment 8 months after introduction of the protocol
This study wants to evaluate the level of satisfaction with surgeons and OR scheduling staff regarding the newly implemented protocol.The investigators will do so by scoring satisfaction on numeric rating scales(NRS).The research team will evaluate:
General satisfaction by means of a numeric rating scale ranging from 0(very dissatisfied) to 10 ( very satisfied).
The new protocol was implemented starting from 01-07-2015. The investigators will evaluate general satisfaction 8 months after implementation( period of 01-02-2016 till 01-03-2016).
Time frame: assessment up to 8 months after introduction of the protocol
The research team will evaluate whether this new protocol has simplified the OR schedule. The investigators will do so by means of a numeric rating scale ranging from 0(not true at all) up to 10(absolutely true) which has to be answered by surgeons and OR scheduling staff.
The investigators will evaluate this up to 8 months after introduction of the new protocol(period of 01-02-2016 till 01-03-2016).The new protocol was implemented starting from 01-07-2015.
Time frame: assessment up to 8 months after introduction of the protocol
The investigators will evaluate the level of satisfaction regarding the new type of surgical gloves in case the surgeon had to switch. We will do so by means of a numeric rating scale ranging from 0 (very unsatisfied) up to 10 (very satisfied). The investigators will evaluate this up to 8 months after introduction of the new protocol( period of 01-02-2016 till 01-03-2016).The new protocol was implemented starting from 01-07-2015.
Jessa Hospital
Other
Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05515276
Allergy, COVID-19
Kilis, Turkey (Türkiye)
View Trial DetailsNCT06687512
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ahmedabad, Gujarat, India
View Trial DetailsNCT02046083
Food Hypersensitivity, Hypersensitivity
Clermont-Ferrand, France
View Trial DetailsNCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial Details